Aspen Neuroscience Aspen Neuroscience, Inc. – a clinical-stage biotechnology company pioneering autologous regenerative therapies, announced the closing of a $115 million Series C financing round. This significant investment will fuel the continued clinical development of Aspen’s lead program, ANPD001, for moderate to advanced Parkinson’s disease. The Series C round was co-led by OrbiMed, ARCH Venture Partners, Frazier Life Sciences, and Revelation Partners, with participation from …